Guidelines recommend corticosteroids and vasopressin to treat septic shock as per specifi c indications [1] . However, the results from trials evaluating both drugs confl ict. For corticosteroids, the 2002 Annane and colleagues study showed a survival benefi t for hydrocortisone/fl udro cortisone treatment in patients with an inappropriate cortisol response to a high-dose adrenocorticotropic hormone (ACTH) test [2], while the Corticosteroid Th erapy of Septic Shock (CORTICUS) trial found no diff erence in survival by patients' response to ACTH [3] . Th e Vasopressin and Septic Shock Trial (VASST) demon strated a survival benefi t in less severe septic shock, but guidelines espouse use 'in patients refractory to other vasopressors' [1, 4] . Clinical variability, leading to over treatment, may have negative eff ects on survival. To evaluate the impact of these evi dence limitations, we surveyed physicians in the Critical Illness Outcomes Study (CIOS).
Guidelines recommend corticosteroids and vasopressin to treat septic shock as per specifi c indications [1] . However, the results from trials evaluating both drugs confl ict. For corticosteroids, the 2002 Annane and colleagues study showed a survival benefi t for hydrocortisone/fl udro cortisone treatment in patients with an inappropriate cortisol response to a high-dose adrenocorticotropic hormone (ACTH) test [2] , while the Corticosteroid Th erapy of Septic Shock (CORTICUS) trial found no diff erence in survival by patients' response to ACTH [3] . Th e Vasopressin and Septic Shock Trial (VASST) demon strated a survival benefi t in less severe septic shock, but guidelines espouse use 'in patients refractory to other vasopressors' [1, 4] . Clinical variability, leading to over treatment, may have negative eff ects on survival. To evaluate the impact of these evi dence limitations, we surveyed physicians in the Critical Illness Outcomes Study (CIOS).
We developed a 15-item, self-administered survey to charac terize physician practice patterns for use of corticosteroids and vasopressin in septic shock. Th e survey, conducted anonymously and with implied consent, was distributed to 92 members of the CIOS listserv. Recipients were encouraged to solicit survey completion by their colleagues. CIOS is a multicenter study among 68 ICUs designed to determine whether ICU-based organi zational and structural factors are associated with patientrelated outcomes. Th e survey fulfi lled Stanford Institutional Review Board exemption guidelines. To address when clinicians would use corticosteroids, we asked partici pants to rate their agreement (fi ve-point Likert scale) for the following situations: blood pressure poorly responsive to fl uid resuscitation and vasopressor therapy; an inappropriate response to ACTH testing [2] ; and a history of treatment with corticosteroids within the prior 6 months. Likert responses were evalu ated by Pearson correlation coeffi cients. For vasopressin, we asked whether physicians preferentially used vaso pressin in more or less severe septic shock, as defi ned by the VASST [4] . Per 140 completed surveys (87% from academic institutions), corticosteroids and vasopressin were used commonly in septic shock (90% and 99%, respectively). Th irty-nine percent used corticosteroids in more than one-quarter of septic shock patients (Figure 1 ). Eighteight percent of respondents agreed with Surviving Sepsis guidelines for blood pressure-based corticosteroid therapy; however, fewer agreed with ACTH-based (47%) or history-based (62%) indications ( Figure 2 ). Agreement with these indications among providers was poorly correlated: 0.38 between blood pressure and ACTH indica tions, and 0.13 between blood pressure and history. Eighty-seven per cent used vasopressin in more severe septic shock.
Substantial variability exists in use of corticosteroids and vasopressin in septic shock. Although agreement exists regarding the use of corticosteroids for refractory hypotension, other indications demonstrated poor to modest guideline concordance. Nearly one-third of respondents considered failure to respond to an ACTH test as an appropriate indication for corticosteroid use, despite negative results from the CORTICUS trial and variability of current cortisol assays [3, 5] . Overtreatment with corticosteroids could increase incidence of secondary infections [3] . Vasopressin use contradicted the conclu sions from the VASST [4] . As septic shock mortality remains high, work is needed to reduce variability through research and adherence to evidence from clinical trials [2] [3] [4] .
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